MorphoSys Provides Statement on Response to COVID-19
MorphoSys is taking measures to mitigate the impact of the rapidly evolving global COVID-19 pandemic on its employees, patients and the broader community.
Impact on Employees and Business Operations:
MorphoSys has activated its business continuity plans to minimize business disruption and ensure the well-being of its staff. A number of actions were implemented, aiming at slowing the spread of COVID-19 and to protect the health and safety of our employees and their families, including a mandatory work-from-home policy for those able to perform their jobs from home, flexible work schedules, restrictions on in-person meetings, visitor access to MorpoSys sites and business travel.
MorphoSys is conducting a number of clinical studies with its investigational medicines, and is closely monitoring each program individually and the overall situation. The Company is making adjustments where necessary, responding to regulatory, institutional, and government guidance and policies related to COVID-19. The top priority is to ensure the safety of all participants in its clinical programs and the integrity of the studies in which they participate.
An increasing number of clinical trial sites are restricting site and patient visits to protect both site staff and patients from possible COVID-19 exposure. Consequently, MorphoSys is continuously monitoring the situation and deciding how to proceed on a “study-by-study” and “country-by-country” basis to ensure patient safety and data integrity.
- Accordingly, enrollment/screening of patients in the M-PLACE study with MOR202 is temporarily paused. This could lead to delays in previously communicated timelines.
- Enrollment of patients will continue in studies with the potential for significant benefit in life-threatening indications.
- Already enrolled patients will continue to receive study drug.
The Company remains committed to maintaining its development plans but acknowledges the potential impact on clinical studies given the rapidly evolving global environment.
MorphoSys maintains previously communicated guidance on its 2020 corporate milestones. However, the situation is highly dynamic and it is not possible to reliably predict or quantify the potential impact on ongoing and planned clinical studies and business operations.
MorphoSys will continue to monitor and evaluate the situation and will provide updates here on its website, and in connection with its upcoming quarterly reportings.